A detailed history of Advisors Capital Management, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Advisors Capital Management, LLC holds 141,115 shares of CSTL stock, worth $3.07 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
141,115
Previous 121,889 15.77%
Holding current value
$3.07 Million
Previous $2.63 Million 18.86%
% of portfolio
0.06%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$18.06 - $25.3 $347,221 - $486,417
19,226 Added 15.77%
141,115 $3.13 Million
Q4 2023

Feb 14, 2024

BUY
$12.19 - $22.43 $60,937 - $112,127
4,999 Added 4.28%
121,889 $2.63 Million
Q3 2023

Nov 15, 2023

BUY
$13.28 - $20.3 $495,583 - $757,555
37,318 Added 46.9%
116,890 $1.97 Million
Q2 2023

Aug 03, 2023

BUY
$11.66 - $26.0 $565,661 - $1.26 Million
48,513 Added 156.2%
79,572 $1.09 Million
Q1 2023

May 04, 2023

SELL
$19.47 - $28.49 $2,959 - $4,330
-152 Reduced 0.49%
31,059 $706,000
Q4 2022

Feb 13, 2023

BUY
$18.08 - $30.0 $78,033 - $129,480
4,316 Added 16.05%
31,211 $735,000
Q3 2022

Nov 16, 2022

BUY
$22.51 - $34.32 $37,771 - $57,588
1,678 Added 6.65%
26,895 $607,000
Q2 2022

Aug 12, 2022

BUY
$16.0 - $45.99 $121,392 - $348,926
7,587 Added 43.03%
25,217 $554,000
Q1 2022

May 10, 2022

BUY
$33.17 - $46.98 $20,465 - $28,986
617 Added 3.63%
17,630 $791,000
Q4 2021

Feb 14, 2022

BUY
$39.06 - $67.58 $113,313 - $196,049
2,901 Added 20.56%
17,013 $729,000
Q3 2021

Nov 12, 2021

BUY
$60.13 - $77.6 $195,602 - $252,432
3,253 Added 29.96%
14,112 $938,000
Q2 2021

Aug 02, 2021

BUY
$50.07 - $76.78 $543,710 - $833,754
10,859 New
10,859 $796,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $572M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Advisors Capital Management, LLC Portfolio

Follow Advisors Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisors Capital Management, LLC with notifications on news.